Cooperative Agreement U01EH000362

This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) will provide $415,712 to Research Triangle Institute (RTI International) to study how public health newborn screening programs should determine which genes to include in sequencing panels. The key objectives are to: Appraise and contrast the approaches and criteria used by experts conducting newborn sequencing studies to determine which genes to screen, synthesizing decision...

The National Institute of Child Health and Human Development (NICHD) awarded a $223,500 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to the University of Alabama for the project "Optimal Newborn Screening Algorithms - Efficacy and Equity." The goal of this 2-year research project is to develop a framework for designing optimal newborn screening algorithms that are accurate and equitable, using cystic fibrosis as a model disorder. Key objectives...

This Project Grant award of $902,046 from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the analytical and clinical validation of the "DuoSeq" assay developed by Data Driven Bioscience Inc. DuoSeq is a novel approach that enables simultaneous DNA and RNA sequencing from a single sample workflow to provide a comprehensive molecular profile for the diagnosis of blood cancers. The project aims to validate DuoSeq's...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Baebies, Inc. to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs). The goal is to create a fully automated, CLIA-waived diagnostic platform that can detect and differentiate viable STI pathogens, such as Chlamydia trachomatis and Neisseria gonorrhoeae,...

The National Institute of Child Health and Human Development (NICHD) awarded a $2,442,535 five-year Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to Harvard Pilgrim Health Care Inc. to investigate the long-term impact and value of implementing newborn genomic sequencing. The project aims to provide critical evidence on how to effectively implement newborn genomic sequencing, manage the resulting findings, and reanalyze data over time to ensure it provides...

This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund the design and preparation of diagnostic biomarker reference standards for mucopolysaccharidosis type I (MPS-I) and type II (MPS-II). These lysosomal storage disorders are included in newborn screening programs, but current first-tier enzyme activity screening has a high rate of false...

This $1,000,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of Helixbind's RAPID/BSI, an automated, culture-free system for the rapid identification of bloodstream infections directly from blood samples. The project aims to complete verification and validation activities to prepare for FDA regulatory clearance of this breakthrough diagnostic technology....

This $153,252 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to develop strategies for identifying individuals at high risk for genetic diseases in order to enable earlier diagnosis and treatment. The award has two key aims: 1) Reevaluating guidelines for universal preconception carrier screening to improve uptake and include new actionable...

This $1,413,007 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development and evaluation of the CRISPR-TB diagnostic tool for detecting tuberculosis (TB) in children under 5 years old. The University of Washington is the primary grantee and will lead a large prospective study of 400 children with suspected TB. The project aims to expand upon prior successful...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...